Skip to main content

Table 2 Cost-effectiveness analysis results

From: Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran

strategy

cost

effect

Incr cost

Incr effect

ICER

enzalutamide

17,541

1.02

1133

0.18

6,260

abiraterone

16,408

0.84

-

-

-

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us